Press Releases

Date Title and Summary Additional Formats
Toggle Summary /C O R R E C T I O N -- Dynavax Technologies Corporation/
/C O R R E C T I O N -- Dynavax Technologies Corporation/ In the news release, Dynavax Reports 2003 Fourth Quarter and Full Year Results, issued earlier today by Dynavax Technologies Corporation (Nasdaq: DVAX) over PR Newswire, the "Additional paid-in capital" line in the "Condensed Consolidated
View HTML
Toggle Summary Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV(TM)
WELLESLEY, Mass. and BERKELEY, Calif., June 28, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY) and Dynavax Technologies Corporation (Nasdaq: DVAX) today announced they have entered into a license agreement relating to certain TLR
View HTML
Toggle Summary Company Profile for Dynavax Technologies
Feb 27, 2009 (BUSINESS WIRE) -- Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified pipeline of novel Toll-like Receptor (TLR) based product candidates. Based on Dynavax's proprietary technologies, these products specifically modify the
View HTML
Toggle Summary Data From Two Phase 3 Studies Demonstrate HEPLISAV's Superiority in Immunizing Persons With Diabetes From Hepatitis B
New National Recommendations Announced Today Urge Vaccinations for Unvaccinated Adults With Diabetes Under 60 Years of Age
View HTML
Toggle Summary Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist for Asthma
$2.6 Million Payment From AstraZeneca Due to Dynavax
View HTML
Toggle Summary Dynavax and AstraZeneca Amend Their Agreement for Asthma Drug Candidate
AstraZeneca to Conduct Phase 2a Clinical Study of AZD1419
View HTML
Toggle Summary Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma
BERKELEY, CA -- (MARKET WIRE) -- 10/05/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) and AstraZeneca have amended their existing Collaboration Agreement to accelerate the initiation of clinical development of AZD 1419, a proprietary second-generation TLR-9 agonist for asthma.
View HTML
Toggle Summary Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study
BERKELEY, CA -- (Marketwired) -- 12/08/14 -- Dynavax Technologies Corp. (NASDAQ: DVAX) today announced that the Company and AstraZeneca AB ("AstraZeneca") signed an amendment to the existing Research Collaboration and License Agreement under which AstraZeneca will fully fund and Dynavax will
View HTML
Toggle Summary Dynavax and GlaxoSmithKline Expand Their Worldwide Strategic Alliance
BERKELEY, CA -- (MARKET WIRE) -- 10/21/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the expansion of its worldwide strategic alliance with GlaxoSmithKline (GSK) focused on toll-like receptor (TLR) inhibitors. The addition of a new target, TLR8, entitles Dynavax to receive a
View HTML
Toggle Summary Dynavax and GlaxoSmithKline Select Clinical Candidate in the Endosomal TLR Inhibitor Program
IND-Enabling Studies Underway
View HTML